ERAS
ERAS
NASDAQ · Biotechnology

Erasca Inc

$15.99
+1.32 (+9.00%)
Analyst Consensus
Strong Buy
17
Analysts
High
Coverage
Buy 14 82%
Hold 2 12%
Sell 1 6%
Price Target
Analyst Price Target +54.2% upside
Low Target $19.75
Average Target $24.65
High Target $31.92
Current Price $15.99
Current
$15.99
Target
$24.65
$19.75 $24.65 avg $31.92
Scenario Analysis
Bear Case
$19.75
23.5%
Low target
Base Case
$24.65
+54.2%
Avg target
Bull Case
$31.92
+99.6%
High target
Risk/Reward
4.2x
Highly favorable
Price in Context
52-Week High
$13.28
20.4% from high
52-Week Low
$1.01
+1,483.2% from low
50-Day SMA
$7.48
+113.8% vs SMA
200-Day SMA
$3.25
+392.0% vs SMA
RSI (14)
71.9
Overbought
Target vs 52W High
$24.65
+85.6% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +24.3%
AMGN
Amgen Inc
Hold 42 50% $190.87 -46.1%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +162.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -3.7%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -89.8%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -68.9%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -3.3%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -27.6%